eligibility_summary
Eligible: 18–75 with MM and measurable disease, relapsed/refractory after ≥3 lines (PI, IMiD, anti‑CD38) with progression ≤60 d after last therapy, ECOG 1–2, ≥3‑mo survival, adequate organ/cardiopulmonary function and venous access. Exclude: CNS MM, POEMS/AL amyloidosis, active HBV/HCV/HIV/CMV/EBV, unstable disease, GVHD, autoimmune neuro disease, uncontrolled infection, recent steroids/G‑CSF/surgery/live vaccines/anti‑tumor tx, pregnant/lactating or planning conception ≤2 y.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Bispecific anti-BCMA–GPRC5D CAR-T therapy (autologous, gene-modified T cells). Mechanism: Patient T cells are engineered with a CAR recognizing BCMA (TNFRSF17) and GPRC5D on myeloma cells, CAR engagement activates CD3ζ/costimulatory signaling, driving T-cell proliferation, cytokine release, and cytotoxic killing. Dual targeting aims to reduce antigen escape and address tumor heterogeneity. Conditioning: Fludarabine (purine analog) and cyclophosphamide (alkylator) for lymphodepletion to improve CAR-T expansion. Targets/pathways: Malignant plasma cells expressing BCMA (BAFF/APRIL–NF-κB survival axis) and GPRC5D (orphan GPCR).